Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (Holdings) PLC (TCBP) generates a steady flow of news as a clinical-stage biopharmaceutical company developing allogeneic gamma-delta T cell therapies for cancer and other indications. News coverage on this page focuses on the company’s clinical progress, strategic initiatives, and capital markets developments, helping readers follow how its gamma-delta T cell platform is advancing from early-stage research into later-stage trials and potential new indications.
Many updates relate to TCB008, the company’s lead gamma-delta T cell therapy candidate. Articles highlight milestones in the ACHIEVE Phase II UK clinical trial, including completion of dosing in Cohort A for relapsed or refractory acute myeloid leukemia patients, initial dosing and follow-up in Cohort B minimal residual disease patients, safety findings with no reported drug-related adverse events, and efficacy signals such as stable disease and complete molecular remission in at least one MRD patient. These reports provide insight into how TCB008 is performing in challenging hematologic malignancies.
Other news items cover strategic and corporate actions, such as TC BioPharm’s intention to conduct proof-of-concept preclinical studies of TCB008 in H5N1 (avian “bird flu”), a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved glaucoma treatment, and operational changes including a shift toward a CDMO-based manufacturing model and associated workforce reductions. Capital markets announcements, including an ADS ratio change and the company’s transition from Nasdaq to trading on OTC Markets, are also reported.
Investors and observers can use this news feed to track clinical data readouts, expansion into new therapeutic areas, proposed M&A activity, and listing or ADS structure changes. For those following TCBP, revisiting this page offers a consolidated view of how the company’s gamma-delta T cell programs and broader strategy evolve over time.
TC BioPharm (NASDAQ: TCBP) announced the execution of a non-binding letter of intent to acquire a biotechnology company focusing on CAR-T therapies for refractory cancers and solid tumors. The acquisition target has proven the therapeutic potential of its lead CAR-T candidate for various solid tumors and is also developing a novel allogeneic CAR-T for autoimmune diseases. The potential acquisition aims to expand TC BioPharm's therapeutic platform and bring synergies in CAR development expertise, providing multiple shots on goal for the treatment of various indications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.